Ratings Redcare Pharmacy NV

Equities

RDC

NL0012044747

Real-time Estimate Tradegate Other stock markets 09:04:35 2024-04-26 am EDT			5-day change	1st Jan Change
130 ^EUR	0.00%		+0.85%	-1.14%

02:13pm	REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating	ZD
Apr. 25	REDCARE PHARMACY : Receives a Buy rating from Baader Bank	ZD

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company appears highly valued given the size of its balance sheet.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
REDCARE PHARMACY NV	-1.14%	2.81B		B
WALGREENS BOOTS ALLIANCE, INC.	-32.59%	15.18B		B-
JD HEALTH INTERNATIONAL INC.	-31.97%	10.1B		B
YIFENG PHARMACY CHAIN CO., LTD.	+9.54%	6.12B		C
MATSUKIYOCOCOKARA & CO.	-11.41%	5.97B		C+
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-30.42%	5.65B		B
NAHDI MEDICAL COMPANY	-0.88%	4.71B		D-
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+51.58%	4.26B	-	C
CLICKS GROUP LIMITED	-12.22%	3.58B		B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-16.75%	3.26B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes